#USA #New York #Faruqi & Faruqi #Altimmune

Faruqi & Faruqi Investigates Altimmune

Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation aimed at uncovering any irregularities related to the stock performance of Altimmune, Inc. This action comes after significant losses have been reported by investors following a disappointing announcement concerning the company's Phase 2b clinical trial results. Investors who acquired Altimmune securities between August 10, 2023, and June 25, 2025, are being encouraged to reach out for confidential discussions on their legal options.

Background of Altimmune's Class Action

On June 26, 2025, Altimmune made headlines when it issued a press release detailing the topline results from the IMPACT Phase 2b MASH trial, which aimed to evaluate the effectiveness of Pemvidutide for treating Metabolic Dysfunction-related Fatty Liver Disease. Unfortunately, the company didn't achieve the anticipated statistical significance in its analysis of the primary endpoint concerning fibrosis reduction. This revelation came as a shock to investors, particularly since prior communications from Altimmune had set inflated expectations.

In this trial, while there was a noted positive trend toward fibrosis improvement, the anticipated statistical significance remained elusive due to an unexpectedly high placebo response. When questioned about the implications of this result, company representatives downplayed the fallout, suggesting that more favorable results might emerge from future Phase 3 trials.

Share Price Impact

The fallout was immediate and dramatic; following the announcement, Altimmune's share price plummeted by over 53%, dropping from $7.71 per share on June 25 to just $3.61 the next day. This abrupt decline raised alarms among shareholders and within the investment community regarding the company's transparency and communication regarding trial outcomes.

Role of Lead Plaintiff

Faruqi & Faruqi emphasizes that investors who experienced these financial losses may have the opportunity to participate in a federal securities class action against Altimmune. The lead plaintiff in this case will be the investor who has suffered the most significant financial impact and is representative of other class members. Interested investors can file a motion to act as lead plaintiff, ensuring they have the guidance of counsel to navigate this complex litigation process.

Call to Action for Investors

The law firm is reaching out to all affected shareholders, encouraging them to gather evidence and share any information they may possess regarding Altimmune's activities. This extends to former employees and whistleblowers who may have insights into the company’s conduct leading up to the trial results. Interested individuals are urged to contact Faruqi & Faruqi directly at their dedicated lines to explore potential legal recourse.

Overall, the developments surrounding Altimmune's stock performance are a potent reminder of the inherent risks involved in the investment landscape, particularly within the biotech sector. As the situation continues to unfold, affected investors are urged to remain proactive about their legal rights and options.

To stay updated on developments related to this investigation and potential class action, investors can visit the Faruqi & Faruqi website or follow the firm on social media channels for the latest news and guidance.